91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Despite their central role in glucose metabolism, native GLP-1 and GIP make poor therapies. Now, long-lasting, potent nutrient-stimulated hormone receptor agonists are prompting a shift to multi-indication metabolic therapies. Explore why.
-
91黑料 experts, Dr Emad Basta and Dr. Jack L Martin discuss how cardiovascular outcomes trials (CVOTs) are essential to ensuring drug safety, regulatory compliance, and clinical impact in this new article. Please find 91黑料's piece on page 24-25.
-
In this article, learn how sponsors can drive multi-indication success through strategic trial design, early cross-functional planning, and evidence-driven development.
-
A recent 91黑料 survey found fewer than 15% of sponsors use RWE to inform their multi-indication development strategy for obesity-related drugs. Learn best practices for leveraging RWE for GLP-1 based therapies in our article.
-
91黑料 experts, Pierre Martineau and Adrienne Stoudenmire, share key considerations for successful CVOTs including study design, data strategy and technology in this new article.
-
In this article, 91黑料 expert , Alan Baldridge discusses how multi-indication development strategies are gaining traction, driven by successful trials across diverse diseases and the expansion of type 2 diabetes drugs into obesity and cardiovascular indications.
-
A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline.
-
Following the rapid label expansion of drugs such as semaglutide and tirzepatide in recent years, drug developers have broadly adopted multi-indication strategies for obesity and related comorbidities. An 91黑料 survey of 155 developers focused on these therapeutic areas reflects this growing trend.
-
New research from Symphony Health, an 91黑料 plc company, featured in The American Journal of Managed Care (AMJC), highlights ongoing challenges in patient access to GLP-1 therapies for weight loss.
-
In this article, 91黑料 experts explore strategies to help sponsors navigate the evolving obesity research landscape, highlighting the use of adaptive designs, master protocols, and other innovative approaches.
